News: Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

4,702JPY
9:12pm EST
Price Change (% chg)

¥-16 (-0.34%)
Prev Close
¥4,718
Open
¥4,697
Day's High
¥4,714
Day's Low
¥4,688
Volume
181,600
Avg. Vol
1,839,718
52-wk High
¥5,039
52-wk Low
¥3,694

Search Stocks
Select another date:

Wed, Dec 17 2014

BRIEF-Oncodesign enters into services agreement with Eisai

* Says it has entered into a services agreement with Eisai to develop a new personalized medicine program in earlier line metastatic breast cancer treatment

BRIEF-Hikma Pharma says in partnership with Eisai for epilepsy treatment drug

* Hikma Enters Partnership With Eisai For Distribution Of First-in-class Epilepsy Treatment Fycompa In Middle East

FDA approves Eisai drug for chemotherapy-associated nausea

- The U.S. Food and Drug Administration said on Friday it has approved Japanese pharmaceutical company Eisai's drug Akynzeo to treat nausea and vomiting in patients undergoing chemotherapy for cancer.

FDA approves Eisai drug for chemotherapy-associated nausea

Oct 10 - The U.S. Food and Drug Administration said on Friday it has approved Japanese pharmaceutical company Eisai's drug Akynzeo to treat nausea and vomiting in patients undergoing chemotherapy for cancer.

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

Long-awaited diet pill gets U.S. approval

- A new diet pill Contrave got approval to be sold in the United States on Wednesday, only the third obesity treatment in more than a decade to win approval from the Food and Drug Administration.

Select another date:
Search Stocks